NasdaqGM:ADMABiotechs
A Look At ADMA Biologics (ADMA) Valuation After New 2025–2027 Guidance And SG-001 Progress
ADMA Biologics (ADMA) updated investors with fresh projections through 2027, outlining revenue, adjusted EBITDA and margin expectations that draw directly on yield focused manufacturing changes and a repositioned plasma collection network.
See our latest analysis for ADMA Biologics.
At a share price of $17.95, ADMA Biologics has given investors a 90 day share price return of 20.07%, while the 1 year total shareholder return sits at 8.85%, building on a very large 5 year total shareholder...